Latest Distributions News

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

McLaren Minerals has secured critical tenement transfers and completed a heritage survey, setting the stage for drilling at its McLaren Titanium Project in Western Australia. The company is progressing steadily towards a pre-feasibility study expected in Q2 2025.

Aeris Environmental Ltd reported a 5% revenue increase to $766,000 in the December 2024 quarter, driven by strong margins and momentum in its AerisTech joint venture. The company’s expanding customer base and strategic partnerships signal promising growth in smart building solutions and consumables.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

Visioneering Technologies reported a mixed Q4 FY'24 with a slight revenue decline but stronger cash flow and expanding global footprint, underpinned by promising clinical trial data.

Latin Resources has secured shareholder and court approvals for its acquisition by Pilbara Minerals, marking a pivotal transition for the Salinas Lithium Project in Brazil. The deal positions Salinas as a key global lithium asset under new stewardship.

Following a recent unitholder meeting, One Managed Investment Funds Limited has initiated the orderly liquidation of the Fat Prophets Global Property Fund’s portfolio, signaling a significant transition for investors.

Uscom Limited reports a 56% increase in cash on hand to $2.17 million for Q2 2024, driven by strategic moves in China and new product regulatory approvals.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.